Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:FPRX

Five Prime Therapeutics (FPRX) Stock Price, News & Analysis

Five Prime Therapeutics logo

About Five Prime Therapeutics Stock (NASDAQ:FPRX)

Advanced Chart

Key Stats

Today's Range
$38.00
$38.00
50-Day Range
$37.65
$38.00
52-Week Range
$2.61
$38.90
Volume
N/A
Average Volume
1.98 million shs
Market Capitalization
$1.77 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive FPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Five Prime Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

FPRX Stock News Headlines

Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.tc pixel
CMMB Chemomab Therapeutics Ltd.
What Is The Prime Rate Today?
See More Headlines

FPRX Stock Analysis - Frequently Asked Questions

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) released its quarterly earnings results on Friday, November, 6th. The biotechnology company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by $0.14. The biotechnology company had revenue of $2.05 million for the quarter, compared to the consensus estimate of $3.50 million. Five Prime Therapeutics had a negative net margin of 554.71% and a negative trailing twelve-month return on equity of 75.84%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Five Prime Therapeutics investors own include Bristol Myers Squibb (BMY), Gilead Sciences (GILD), OPKO Health (OPK), Pfizer (PFE), Nektar Therapeutics (NKTR), Advanced Micro Devices (AMD) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
11/06/2020
Today
8/29/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FPRX
CIK
1175505
Fax
N/A
Employees
87
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($3.92)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$137.20 million
Net Margins
-554.71%
Pretax Margin
N/A
Return on Equity
-75.84%
Return on Assets
-49.08%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.35
Quick Ratio
5.35

Sales & Book Value

Annual Sales
$14.87 million
Price / Sales
119.01
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.13 per share
Price / Book
9.20

Miscellaneous

Outstanding Shares
46,572,000
Free Float
N/A
Market Cap
$1.77 billion
Optionable
Optionable
Beta
4.40
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:FPRX) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners